Placebo News and Research

RSS

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Clinical trials used by the Food and Drug Administration (FDA) to approve new drugs between 2005 and 2012 vary widely in their characteristics, according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Several potentially preventable deficiencies, including failure to select optimal drug doses and suitable outcome measures for a study, accounted for significant delays in the approval of new drugs by the Food and Drug Administration (FDA), according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Gene therapy edges closer for Parkinson’s disease

Lentiviral vector-based gene therapy is well tolerated and may improve motor function in patients with Parkinson’s disease, shows an open-label study published in The Lancet.

20 Jan 2014

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

A long-shot lawsuit that could have damaged the effectiveness of health care reform got a well-deserved brushoff from a federal district judge on Wednesday.

20 Jan 2014

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

Brain imaging experiments have revealed for the first time how ecstasy produces feelings of euphoria in users.

17 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Continued use of statins may help prevent delirium in critically ill patients

Continued use of statins may help prevent delirium in critically ill patients who received statins before hospital admission, according to a new study of 470 intensive care patients in the UK.

17 Jan 2014

Robot-assisted therapy shows increased mobility after paresis

The survivors of a stroke often struggle with persistent loss of function of the central nervous system. Around the world strokes are one of the most frequent causes of paresis.

17 Jan 2014

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Patients with fibromyalgia syndrome (FMS) typically have widespread chronic pain and fatigue. For those with low vitamin D levels, vitamin D supplements can reduce pain and may be a cost-effective alternative or adjunct to other treatment, say researchers in the January 2014 issue of PAIN-.

17 Jan 2014

Longer reads: Connecting with patients; obesity origins; children with chronic disease

I'd never [before] been encouraged to sit at a patient's bedside -; to stop hurrying for even a moment. Our medical teachers put a premium on accuracy and efficiency, which became conflated with speed.

17 Jan 2014

Traditional Chinese herbal medicines hold promise for slowing progression of diabetes

Traditional Chinese herbal medicines hold promise for slowing the progression from prediabetes to an official diabetes diagnosis, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

17 Jan 2014

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

Researchers at Wayne State University have discovered a potential way to improve the lipid profiles in patients undergoing hemodialysis that may prevent cardiovascular disease common in these patients.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

Biogen Idec today announced that FAMPYRA (prolonged-release fampridine tablets) has been made available in Ireland for the symptomatic treatment of walking impairment in adults with Multiple Sclerosis. FAMPYRA is a prescription drug and is licensed for use in all types of the disease, including the progressive forms. FAMPYRA is available by way of retail pharmacy on a private payment basis.

15 Jan 2014

Study shows that high-blood pressure medicine may also prevent migraines

Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).

13 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

10 Jan 2014

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.

10 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

Placebo News and Research

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Potentially preventable deficiencies account for significant delays in approval of new drugs by FDA

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Gene therapy edges closer for Parkinson’s disease

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

FDA approves New Drug Application for PENNSA 2%

Continued use of statins may help prevent delirium in critically ill patients

Robot-assisted therapy shows increased mobility after paresis

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Longer reads: Connecting with patients; obesity origins; children with chronic disease

Traditional Chinese herbal medicines hold promise for slowing progression of diabetes

New way to improve lipid profiles in patients undergoing hemodialysis may prevent heart attack

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

Study shows that high-blood pressure medicine may also prevent migraines

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News